Subscribe to RSS
Formulation, Characterization, and the Diuretic Effects of a New Intravenous Metolazone Emulsion
Objective Acute decompensated heart failure is often treated with a combination of loop and thiazide-like diuretics. Of these thiazide-like diuretics, two common choices are intravenous chlorothiazide or oral metolazone. Metolazone is more potent and has a longer duration of action, but since it is an oral formulation, it has a longer on-set time as compared to chlorothiazide. In addition, metolazone is poorly water-soluble, thereby rendering intravenous formulation more challenging. To address these issues, we proposed the formulation of a solvent-free metolazone emulsion for intravenous administration.
Methods An oil-in-water emulsion containing 1 mg/mL of metolazone was formulated by homogenizing soybean oil and l-lecithin in water in the presence of optimized concentrations of glycerin with tween 80 or poloxamer 188 as surfactant. The emulsion was characterized on the basis of particle size, zeta potential, morphology and metolazone release kinetics. The diuretic effect of the metolazone emulsion was evaluated in rats.
Results The 1 mg/mL metolazone emulsion prepared with 5% tween 80 displayed the best physical stability. The emulsion exhibited a hydrodynamic diameter of 157.13±1.52 nm. About 93% of metolazone was released from the formulation within 2 h. The 2 mg/kg and 4 mg/kg dose of the metolazone emulsion increased urine output in the rats by 68.9 and 134%, respectively, as compared to control rats. Furthermore, the 4 mg/kg dose exhibited a 168.8%, 25.8%, and 150.9% increase in sodium, potassium, and chloride, respectively.
Conclusion This metolazone emulsion was capable of increasing urine volume output and demonstrated both natriuretic and kaliuretic properties.
Received: 05 March 2022
Accepted: 28 March 2022
Article published online:
10 May 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Joseph SM, Cedars AM, Ewald GA. et al. Acute decompensated heart failure: Contemporary medical management. Texas Hear Inst J 2009; 36: 510-520
- 2 Moranville MP, Choi S, Hogg J. et al. Comparison of Metolazone Versus Chlorothiazide in Acute Decompensated Heart Failure with Diuretic Resistance. Cardiovasc Ther 2015; 33: 42-49
- 3 Mozaffarian D, Benjamin EJ, Go AS. et al. Heart disease and stroke statistics-2015 update : A report from the American Heart Association. Circulation 2015; 131: e29-e39
- 4 Ambrosy AP, Fonarow GC, Butler J. C et al. The global health and economic burden of hospitalizations for heart failure: Lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63: 1123-1133
- 5 Heidenreich PA, Albert NM, Allen LA. et al. Forecasting the impact of heart failure in the united states a policy statement from the american heart association. Circ Hear Fail 2013; 6: 606-619
- 6 Hunt SA, Abraham WT, Chin MH. et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the Aamerican College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-e479
- 7 Yancy CW, Jessup M, Bozkurt B. et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 2013; 62: e147-e239
- 8 Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16: e1
- 9 Shulenberger CE, Jiang A, Devabhakthuni S. et al. Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance. Pharmacotherapy 2016; 36: 852-860
- 10 Gong H, Geng S, Zheng Q. et al. An intravenous clarithromycin lipid emulsion with a high drug loading, H-bonding and a hydrogen-bonded ion pair complex exhibiting excellent antibacterial activity. Asian J Pharm Sci 2016; 11: 618-630
- 11 Kwasigroch B, Escribano E, Morán MdelC. et al. Oil-in-water nanoemulsions are suitable for carrying hydrophobic compounds: Indomethacin as a model of anti-inflammatory drug. Int J Pharm 2016; 515: 749-756
- 12 Kumar P, Nagarajan A, Uchil PD. Analysis of Cell Viability by the alamarBlue Assay. Cold Spring Harb Protoc 2018; 2018: 462-464
- 13 Gonyon T, Carter PW, Trouilly JL. Conformance with USP chapter 729 for parenteral nutritional emulsions. Am J Heal Pharm 2008; 65: 1117-1118
- 14 Entegris, Inc. USP<729>Globule Size Distribution in Lipid Injectable Emulsions. n.d
- 15 Lindquist DE, Rowe AS, Heidel E. et al. Evaluation of the Hemodynamic Effects of Intravenous Amiodarone Formulations During the Maintenance Phase Infusion. Ann Pharmacother 2015; 49: 1317-1321
- 16 Gupta V, Trivedi P. In vitro and in vivo characterization of pharmaceutical topical nanocarriers containing anticancer drugs for skin cancer treatment. Lipid Nanocarriers Drug Target., Elsevier; 2018, p. 563–627
- 17 Samimi S, Maghsoudnia N, Eftekhari RB. et al. Lipid-Based Nanoparticles for Drug Delivery Systems. Charact Biol Nanomater Drug Deliv Nanosci Nanotechnol Drug Deliv 2019; 47-76
- 18 Lockman PR, Koziara JM, Mumper RJ. et al. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target 2004; 12: 635-641
- 19 Ahlschwede KM, Curran GL, Rosenberg JT. et al. Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer’s disease brain. Nanomedicine Nanotechnology, Biol Med. 2018
- 20 Cvetanovic I, Ranade V, Molnar J. et al. The evaluation of the diuretic action of parenteral formulations of metolazone. Am J Ther 2007; 14: 25-29
- 21 Al Shoyaib A, Archie SR, Karamyan VT. Intraperitoneal route of drug administration: should it be used in experimental animal studies. Pharm Res 2020; 37: 12
- 22 Johansen PB. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother Pharmacol 1981; 54: 267-270
- 23 Guichard S, Chatelut E, Lochon I. et al. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol 1998; 422: 165-170
- 24 Soma D, Kitayama J, Ishigami H. et al. Different Tissue Distribution of Paclitaxel With Intravenous and Intraperitoneal Administration. J Surg Res 2009; 155: 142-146